CD9 and neoplasm: Using an ILN biochip assay with proper antibodies, we sorted exosome‐rich (Exo) subpopulations using CD63/CD9/CD81 antibodies, microvesicle‐rich (MV) subpopulations using ARF6/Anexin A1 antibodies, and tumor‐associated EVs (tEV) using SCLC specific membrane proteins such as DLL3, EpCAM and ROR1 antibodies.